• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Tonix Pharmaceuticals Holding Corp.

Monday, June 03, 2024
CP
CNS/Neurological
Tonix is a biopharmaceutical company with a development portfolio focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and acute stress disorder (ASD). Although CNS is our primary focus, Tonix’s pipeline is also comprised of immunology, rare disease, and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our rare disease portfolio includes therapeutics to treat rare genetic conditions including Prader-Willi syndrome, for which we have received FDA Orphan Drug Designation.
Tonix Pharmaceuticals Holding Corp.
Company Website: https://www.tonixpharma.com/
Lead Product in Development: TNX-102 SL (Tonmya is the conditionally accepted trade name) for the management of fibromyalgia.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4

Exchange

NASDAQ

Ticker

TNXP

Company HQ City

Chatham

Company HQ State

New Jersey

Company HQ Country

United States

CEO/Top Company Official

Seth Lederman, MD

Development Phase of Primary Product

NDA Preparation/In Review
Speakers
Jessica Morris
Chief Operating Officer
TONIX Pharmaceuticals
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS